Interdisciplinary Symposium on Osteoporosis 2026 (ISO2026)
Highlights from Margie Bissinger
Time Line:
- [00:00] - FDA approves total hip BMD as endpoint for drug trials
- [01:57] - Oral Forteo: first pill version of anabolic drug
- [04:29] - Removal of estrogen black box warning and implications
- [10:16] - Estrogen for bone health, heart, and colon protection
- [11:36] - Short-course anabolic therapy vs. maintenance therapy
- [16:35] - Importance of medication sequencing
- [24:30] - Bone turnover markers for monitoring progress
- [32:04] - New screening guidelines for women
- [37:55] - Bone medication and cardiovascular risk
- [40:07] - The use of AI in diagnostics
- [43:18] - Interdisciplinary care and referrals to physical therapy